Which country is Sotoracib (AMG510) produced in?

Sotoracib, also known as AMG 510, is developed and produced by Amgen, a world-renowned biopharmaceutical company. Amgen was founded in 1980 and is headquartered in Thousand Oaks, California, USA. It is a multinational company focusing on the field of biotechnology and is committed to the development and production of innovative biopharmaceutical products, especially for diseases with unmet clinical needs.

The research and development of AMG 510representsAmgen’s long-term investment and commitment in the field of oncology treatment. As a leading biotechnology company, Amgen has extensive research and development experience in cancer to develop novel targeted therapies to improve patient survival and quality of life.

The development of sotoraxib began with in-depth research on tumor genomics, especially the understanding ofKRAS G12Cmutation. Amgen’s scientific team used advanced technology and innovative drug design methods to successfully develop sotorasibu, a drug targeting KRAS G12C mutations, providing a new treatment option for patients with KRAS mutations.

Amgen has demonstrated outstanding technical capabilities and scientific leadership during the clinical research and development of sotorasib. Their clinical trials were rationally designed and the research was rigorously executed, laying a solid foundation for the successful development of sotoraxib.

The launch of sotorasiib marks another important breakthrough for Amgen in the field of cancer, bringing new hope to cancer patients. As a biopharmaceutical company committed to innovation, Amgen will continue to invest resources in the field of tumor treatment and is committed to developing more innovative treatment options to meet clinical needs and improve patients' survival and quality of life.